Gastroenterology · Peptic Ulcer Disease
The facts most likely to be tested
Zollinger-Ellison syndrome is caused by a gastrin-secreting tumor (gastrinoma) leading to gastric acid hypersecretion and refractory peptic ulcer disease.
The most sensitive initial screening test is a fasting serum gastrin level, which will be markedly elevated.
A secretin stimulation test is the gold standard for confirming the diagnosis when serum gastrin levels are non-diagnostic, as secretin paradoxically increases gastrin release in gastrinoma patients.
Patients frequently present with chronic diarrhea and steatorrhea due to the inactivation of pancreatic enzymes by the excessive gastric acid.
Gastrinomas are strongly associated with Multiple Endocrine Neoplasia type 1 (MEN1), characterized by the 3 Ps: parathyroid, pancreas, and pituitary tumors.
The most common location for a gastrinoma is the gastrinoma triangle, defined by the junction of the cystic and common bile ducts, the second and third portions of the duodenum, and the neck and body of the pancreas.
Initial management of the acid hypersecretion requires high-dose proton pump inhibitors (PPIs), while definitive treatment involves surgical resection of the tumor.
Vignette unlocked
A 45-year-old man presents with a 6-month history of burning epigastric pain and frequent, foul-smelling stools. He has failed multiple courses of standard-dose PPI therapy for presumed GERD. Physical examination reveals epigastric tenderness. Laboratory studies show a fasting serum gastrin level of 1,200 pg/mL (normal <100 pg/mL) and a gastric pH of 1.5. His medical history is significant for hypercalcemia and a recent diagnosis of a prolactinoma.
What is the most likely underlying genetic syndrome associated with this patient's condition?
Multiple Endocrine Neoplasia type 1 (MEN1)
The patient's presentation of refractory ulcers and hypergastrinemia is classic for Zollinger-Ellison syndrome, which is associated with MEN1 (parathyroid, pancreas, and pituitary tumors).
Full handout
High yield triage
Etiology / Epidemiology
Caused by a gastrin-secreting tumor (gastrinoma) often associated with MEN1 syndrome.
Clinical Manifestations
Presents with refractory peptic ulcer disease and chronic diarrhea.
Diagnosis
Gold standard is the fasting serum gastrin level (>1000 pg/mL) and secretin stimulation test.
Treatment
High-dose proton pump inhibitors are first-line; surgical resection is the only curative option.
Prognosis
Malignancy potential is high; 60-90% of gastrinomas are malignant.
Full handout
Epidemiology & Etiology
Most cases are sporadic, but 25% are associated with Multiple Endocrine Neoplasia type 1 (MEN1). These tumors are typically located in the gastrinoma triangle. They are most common in patients aged 30-50.
Pertinent Anatomy
The gastrinoma triangle is defined by the confluence of the cystic and common bile ducts, the second and third portions of the duodenum, and the neck/body of the pancreas. This anatomical region contains the vast majority of gastrinomas.
Pathophysiology
Excessive gastrin secretion leads to parietal cell hyperplasia and massive gastric acid hypersecretion. This overwhelms the buffering capacity of the duodenum, causing refractory peptic ulcers. The acidic environment also inactivates pancreatic enzymes, leading to steatorrhea and malabsorption.
Clinical Manifestations
Patients present with abdominal pain, chronic diarrhea, and weight loss. Look for ulcers distal to the duodenal bulb or multiple ulcers. Red flags include ulcers that are unresponsive to standard therapy or recurrent after H. pylori eradication.
Diagnosis
The fasting serum gastrin level is the initial screening test; levels >1000 pg/mL with gastric pH <2 are diagnostic. If gastrin is elevated but not diagnostic, the secretin stimulation test is the gold standard, showing a paradoxical rise in gastrin. Somatostatin receptor scintigraphy (OctreoScan) is used for tumor localization.
Treatment
High-dose proton pump inhibitors (e.g., omeprazole) are required to control acid hypersecretion. Surgical resection is the only potential cure for localized disease. Avoid NSAIDs as they exacerbate mucosal injury in an already hyperacidic environment.
Prognosis
Prognosis depends on the presence of liver metastases, which are the primary determinant of survival. 60-90% of gastrinomas are malignant, requiring long-term monitoring of gastrin levels and imaging.
Differential Diagnosis
H. pylori gastritis: usually responds to standard triple therapy
Antral G-cell hyperplasia: gastrin levels do not rise with secretin
Retained gastric antrum: history of prior gastric surgery
Systemic mastocytosis: associated with elevated histamine, not gastrin
Chronic PPI use: causes hypergastrinemia but with elevated gastric pH